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Abstract:  Background: Most patients with primary biliary cirrhosis (PBC) are treated with ursodeoxycholic acid 
(UDCA); however, some do not respond fully. PBC is also associated with dyslipidemia, but a link with vascular risk has 
not been confirmed. 
Methods and Results: In this study we compared UDCA monotherapy with fenofibrate plus UDCA in PBC patients with 
incomplete biochemical response to UDCA monotherapy for  8 months. Ten patients (57.2±13.3 years old) with PBC 
and persistent elevations of liver enzymes after treatment with UDCA (600 mg/day) were randomized to continue UDCA 
(4 patients) or to receive micronized fenofibrate (200 mg/day) plus UDCA (6 patients) for 8 weeks. Significant reductions 
in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment 
group. The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also de-
creased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively). In 
contrast, no significant alterations in liver enzymes or lipid profile were observed in patients who continued UDCA mono-
therapy. The changes in the lipid and enzyme variables differed significantly (p<0.03) between the 2 groups. Fenofibrate 
was well tolerated.  
Conclusions: The administration of fenofibrate plus UDCA seems to be safe and may improve lipid and liver indices in 
patients with PBC who do not respond fully to UDCA monotherapy. Whether the improved lipid profile translates into a 
decreased risk of vascular events remains to be established.  
Keywords: Fibrates, ursodeoxycholic acid, primary biliary cirrhosis, liver enzymes, dyslipidemia.  
INTRODUCTION 
  Primary biliary cirrhosis (PBC) is a chronic cholestatic 
liver disease characterized by inflammation and destruction 
of interlobular bile ducts, which may eventually lead to liver 
fibrosis, biliary cirrhosis and subsequently hepatic failure 
and death [1]. Although there is no established aetiology for 
the disease, PBC has been attributed to autoimmunity pri-
marily due to its association with autoantibodies [especially 
antimitochondrial antibodies (AMA)] and elevated levels of 
immunoglobulin M (IgM) [1].  
  Ursodeoxycholic acid (UDCA), the most commonly used 
drug for PBC,[2] may ameliorate cholestasis [2]. However, 
some patients do not achieve complete biochemical response 
with UDCA treatment [3]. Fibrates (mainly bezafibrate), 
which are potent ligands of peroxisome proliferator-activated 
receptor  (PPAR), have been tested in patients with PBC 
with promising results [4-11]. However, there are scarce   
data on the effects fenofibrate (a commonly used fibrate)   
in PBC. Therefore, we conducted this pilot study to com- 
pare the effects of UDCA monotherapy with the combina- 
tion of UDCA and fenofibrate in patients with PBC who   
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had incomplete biochemical response following UDCA 
monotherapy for 8 months.  
  PBC is associated with dyslipidemia. However, it has   
not been established if this represents an increased risk   
of cardiovascular disease (CVD) [12]. Therefore, using a 
fibrate in patients with PBC may potentially improve both 
PBC-related liver damage and vascular risk.  
MATERIALS AND METHODOLOGY 
Participants 
  Ten patients (2 men and 8 women, 57.2±13.3 years old) 
with histologically confirmed PBC (stages I and II) were 
included in the present study. These patients had persistent 
elevations of liver enzyme activities [specifically: alkaline 
phosphatase (ALP) >3-fold upper limit of normal] after 
treatment with UDCA (600 mg/day) for at least 8 months. 
Patients with known CVD, diabetes mellitus, cancer, renal 
disease (serum creatinine levels >1.6 mg/dL) and hypothy-
roidism [thyroid stimulating hormone (TSH) >5 IU/mL] 
were excluded from the study. Patients taking lipid lowering 
drugs or having stopped them less than 6 weeks before study 
entry, as well as those currently taking other drugs that affect 
lipid metabolism (e.g. beta-blockers, thiazide diuretics, con-
traceptive pills or steroids) were also excluded. The patients  
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or receive combined treatment with micronized fenofibrate 
(200 mg/day) and UDCA (600 mg/day) for 8 weeks (6   
patients). Patients were instructed to follow their usual diet. 
Compliance with medication was assessed by pill count.   
All participants gave their written informed consent prior   
to enrolment and the Ethics Committee of the University 
Hospital of Ioannina approved the study protocol.  
Laboratory Determinations 
  The activities of ALP, aspartate aminotransferase (AST) 
alanine aminotransferase (ALT) gamma glutamyl trans- 
peptidase (GT) and amylase as well as the levels of glucose, 
total and conjugated bilirubin, uric acid, creatinine and the 
lipid profile [i.e. total cholesterol, high density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol 
(LDL-C), non-HDL-C and triglycerides] were assessed at 
baseline before randomization and after 8 weeks of treat-
ment. The samples were collected after an overnight fast and 
assayed in the laboratory of the University Hospital of Ioan-
nina using an Olympus AU 600 analyzer (Olympus Diagnos-
tica GmbH, Hamburg, Germany). Glucose was measured by 
the hexokinase method. LDL-C levels were calculated using 
the Friedewald equation (LDL-C = total cholesterol – HDL-
C – triglycerides/5 in mg/dL) and non-HDL-C was defined 
as total cholesterol – HDL-C. 
Statistical Analysis 
  All parameters were checked for normality using the 
Kolmogorov-Smirnov test. All values are expressed as mean 
± standard deviation (SD) except for non-Gaussian distrib-
uted variables which are expressed as median (range). The 
paired-samples  t-test (or Wilcoxon’s rank test for non-
Gaussian parameters) was used for assessing the effect of 
treatment in each group. Analysis of covariance (ANOVA), 
adjusted for baseline values, was used for comparisons be-
tween treatment groups. Significance was defined as 
p<0.049 due to multiple comparisons (x2) [13]. All analyses 
were carried out using the SPSS 15.0 statistical package for 
Windows (SPSS Inc., Chicago, Illinois). 
RESULTS 
  Baseline characteristics of the participants did not differ 
between the 2 groups (Table 1). Body mass index (BMI) did 
not change during the study in either group. 
  The addition of fenofibrate to UDCA resulted in signifi-
cant decreases in the levels of total cholesterol, triglycerides 
and non-HDL-C (Table 2). Furthermore, significant reduc-
tions in the serum activities of ALP (-32.6%, p=0.012), GT 
(-44%, p=0.04) and ALT (-16.9%, p=0.029) compared with 
baseline were observed in the combination treatment group 
(Table  2). On the other hand, no significant alterations in 
liver enzyme activities and lipid profile were demonstrated 
in patients who continued on UDCA monotherapy (Table 2). 
The change in the lipid and liver enzyme variables differed 
significantly (p<0.03) between the 2 groups (Table 2). No 
significant changes in glucose, total and conjugated biliru-
bin, uric acid, amylase, creatinine and AST compared with 
baseline were observed in the 2 treatment groups.  
  Fenofibrate was well tolerated by all patients.  
DISCUSSION 
  Significant improvements in lipid profile and liver en-
zyme activities were demonstrated in PBC patients who had 
an incomplete biochemical response to UDCA monotherapy 
and now received combined fenofibrate+UDCA treatment. 
In contrast, no change in these parameters was noted in the 
patients who continued on UDCA monotherapy. 
  Several small studies have investigated the effects of 
fibrates, either alone or in combination with UDCA in pa-
tients with PBC [5-7, 10, 14, 15]. In a prospective pilot study 
23 patients with PBC who had been treated with UDCA for 
1-5 years were randomly assigned to continue UDCA treat-
ment (600 mg/day, n=13) or receive UDCA (600 mg) and 
bezafibrate (400 mg) (n=10) for 12 months [7]. Significant 
reductions in ALP, GT and IgM at 3 (p<0.05), 6, 9 and 12 
months (p<0.01) were observed in the bezafibrate+UDCA 
treatment group. The decrease in ALP and IgM was more 
pronounced as compared with that in the UDCA monother-
apy group [7]. Comparable results have been demonstrated 
in other studies with similar design [4, 11].  
  Two studies compared the effects of bezafibrate with that 
of UDCA in patients with PBC. In 1 study 24 patients were 
randomly assigned to receive bezafibrate 400 mg/day (n=12) 
or UDCA 600 mg/day (n=12) for 12 months [6]. Significant 
reductions in ALT, ALP, GT and IgM were demonstrated 
in both treatment groups (p<0.0001); these changes were 
more pronounced in patients who received bezafibrate [6]. In 
contrast, in the other study bezafibrate was equally effective 
with UDCA [15]. However, it is not known whether these 
effects were translated into histological improvement as no 
biopsies were performed in the aforementioned studies.  
  There is few data in literature regarding the long-term 
efficacy of bezafibrate in patients with PBC [5, 10, 16]. Na-
kamuta et al. followed 3 patients with PBC who were treated 
with bezafibrate (400 mg/day) and UDCA (600 mg/day) for 
an average of 37.5 months after treatment with UDCA for 
more than 4 years [16]. The mean levels of ALT, GT, IgM 
and the titer of AMA were decreased after treatment 
(p=0.079 for ALT and GT and p=0.043 for IgM vs base-
line) [16]. 
  Similar results in biochemical parameters along with   
histological changes were observed in 3 women with PBC 
after bezafibrate administration for 3, 4 and 5 years, respec-
tively [5]. Substantial reductions in the levels of ALT, ALP, 
GT, IgM and AMA, as well as a significant increase in 
apolipoprotein A-II levels were demonstrated in all patients. 
Furthermore, 2 of the 3 patients exhibited histological   
improvement while in the other patient there were no signs 
of deterioration [5]. This report indicated an association be-
tween biochemical and histological changes after bezafibrate 
treatment in PBC patients. In contrast, long-term bezafibrate 
treatment (6.5 and 6 years) did not lead to histological   
improvement in 2 patients with asymptomatic PBC and   
elevated liver enzymes [10].  
  There are some promising results in terms of fibrosis 
progression [9]. Seventeen patients with PBC who received 
bezafibrate (400 mg/day) and UDCA (600 mg/day) were 
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bezafibrate and UDCA was associated with significant re-
ductions in hepatic fibrosis markers [9].  
  The activity of fenofibrate on PPAR is stronger than 
that of bezafibrate,[17] while fenofibrate exhibits more fa-
vourable effects on lipid profile compared with bezafibrate 
[18, 19]. Furthermore, fenofibrate is a commonly used fi-
brate. However, there are only 3 studies on the effects of 
fenofibrate in PBC patients. In 1 study 7 patients with ab-
normal biochemical profile (elevated ALP, GT and IgM) 
despite treatment with UDCA (600-900 mg/day) for 1-8 
years were administered fenofibrate (150-200 mg/day) in 
addition to UDCA [20]. Treatment for 6 months resulted in 
reductions in the levels of these parameters in all 7 patients 
(p<0.05 vs baseline) [20]. In another study fenofibrate was 
added to UDCA for 12 weeks in 9 patients with asympto-
matic PBC who failed to respond to UDCA monotherapy 
[21]. The serum levels of ALP and IgM were significantly 
reduced after fenofibrate treatment (p<0.05), while the titer 
of AMA decreased in 4 of 9 patients. Lipid levels (total cho-
lesterol, LDL-C, HDL-C and triglycerides) did not change 
significantly [21]. Consistently, in a recent study the addition 
of fenofibrate (134-200 mg/day) to UDCA for 23 months 
resulted in significant reductions in IgM (p=0.0015) and 
ALP (p=0.0016) in 16 patients with lack of biochemical re-
sponse (no significant decrease in ALP, ALT or IgM) to 
UDCA monotherapy (for a mean of 22.8 months) [22]. The 
findings of the aforementioned studies are consistent with 
the results of our study, suggesting that fenofibrate may be 
useful for the treatment of PBC, especially in patients resis-
tant to UDCA. 
  Data regarding the long-term effects of fenofibrate   
in PBC is not available. To the best of our knowledge only 
Table 1.  Baseline Characteristics of Study Participants 
  Fenofibrate Plus UDCA (n=6)  UDCA (n=4)  p  Reference Range 
Mean duration of UDCA 
monotherapy (months) 
8.6±0.8 8.8±0.7  NS   
Age (years)  55.3±4.5 54.8±7.3  NS   
Sex (male/female)  1/5  1/3  NS   
Smoking (yes/no)  2/4  1/3  NS   
Body mass index (kg/m
2) 27.2±2.8  27.9±3.1  NS   
ALP (IU/L)   195±73 232±74  NS  30-125 
AST (IU/L)   42±15 38±10  NS  10-35 
ALT (IU/L)   49±25 41±13  NS  10-35 
GT (IU/L)   96 (38-479)  112 (56-419)  NS  10-52 
Total bilirubin (mg/dL)   0.70±0.14  0.73±0.18  NS  0.1-1.0 
Conjugated bilirubin (mg/dL)   0.16±0.04  0.17±0.07  NS  0.0-0.3 
Uric acid (mg/dL)   4.3±1.3  4.1±1.2  NS  3.4-8.0 (men) 2.4-6.1 (women) 
Creatinine (mg/dL)   0.74±0.15  0.76±0.12  NS  0.6-1.2 
Amylase (IU/L)  63±15  68±16  NS  30-90 
Total cholesterol (mg/dL)   283±40  302±45  NS  110-200 
Triglycerides (mg/dL)   145±67  136±68  NS  40-175 
HDL-C (mg/dL)  68±17  71±18  NS  35-70 
LDL-C (mg/dL)  189±29  198±24  NS  Target values depend on individual 
cardiovascular risk 
non HDL-C (mg/dL)  215±27  221±29  NS   
Glucose (mg/dL)   96±19  92±16  NS  70-125 
UDCA: ursodeoxycholic acid, ALP: alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GT: gamma glutamyl transpeptidase, HDL-C: high 
density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, NS: not significant  
Values are expressed as mean ± SD, except for GT which is expressed as median (range) 
To convert bilirubin values to μmol/L multiply by 17.1. To convert uric acid values to μmol/L multiply by 59.48. To convert creatinine values to μmol/L multiply by 88.4. To con-
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Table 2.  Biochemical Biomarkers and Lipid Profile at Baseline (Before Randomization) and After 8 Weeks of Treatment 
  Baseline  8 Weeks  Change (%) 
ALP (IU/L) 
Fenofibrate plus UDCA 
UDCA  
 
195±73 
232±74 
 
132±70 
245±81 
 
-32.6
†,¶ 
+5.6 
AST (IU/L) 
Fenofibrate plus UDCA 
UDCA 
 
42±15 
38±10 
 
41±19 
37±11 
 
-3.0 
-2.0 
ALT (IU/L) 
Fenofibrate plus UDCA 
UDCA 
 
49±25 
41±13 
 
41± 27 
39±14 
 
-16.9
†,¶ 
-5.0 
GT (IU/L) 
Fenofibrate plus UDCA 
UDCA 
 
96 (38-479)  
112 (56-419) 
 
54 (19-348) 
120 (62-430) 
 
-44.0
†,¶ 
+1.0
 
Total bilirubin (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
0.70±0.14 
0.73±0.18 
 
0.64±0.29 
0.65±0.24 
 
-8.5 
-11.0 
Conjugated bilirubin (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
0.16±0.04 
0.17±0.07 
 
0.14±0.09 
0.15±0.08 
 
-12.5 
-12.0 
Uric acid (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
4.3±1.3 
4.1±1.2 
 
4.0±1.5 
4.0±1.3 
 
-7.0 
-2.0 
Creatinine (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
0.74±0.15 
0.76±0.12 
 
0.82±0.13 
0.79±0.12 
 
+6.0 
+4.0 
Amylase (IU/L) 
Fenofibrate plus UDCA 
UDCA 
 
63±15 
68±16 
 
62±10 
62±13 
 
-1.0 
-9.0 
Total cholesterol (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
283±40 
302±45 
 
257±39 
297±39 
 
-9.5
†,¶ 
-2.0 
Triglycerides (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
145±67 
136±68 
 
108±35 
122±28 
 
-25.6
†,¶ 
-10.0 
HDL-C (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
68 ±17 
71±18 
 
68±14 
70±16 
 
0.0 
-1.5 
LDL-C (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
189±29 
198±24 
 
167±22 
201±26 
 
-10.0 
+1.0 
non HDL-C (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
215±27 
221±29 
 
188±29 
209±32 
 
-12.5
†,¶ 
-5.0 
Glucose (mg/dL) 
Fenofibrate plus UDCA 
UDCA 
 
96±19 
92±16 
 
85±11 
94±15 
 
-1.0 
+2.0 
For abbreviations and conversions to SI units see Table 1 
†p<0.049 vs baseline 
¶p<0.03 vs UDCA monotherapy  
Values are expressed as mean ± SD, except for GT which is expressed as median (range). 
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Nakamuta  et al. reported the effects of treatment with   
fenofibrate (150 mg/day) and UDCA (600 mg/day) in 2   
patients with PBC [16]. After an average of 37.5 months   
the mean levels of ALT, GT, IgM and the titer of AMA 
were decreased (p=0.079 for ALT and GT and p=0.043   
for IgM vs baseline) in both patients [16]. It is surprising  
that most of the studies discussed above did not report lipid 
levels. 
  The mechanisms by which fibrates may improve the his-
tology in PBC have not been fully elucidated. These actions 
may be mediated via PPAR, the main target of fibrates, 
which are involved in the inflammatory and immunologic 
response. Fibrates inactivate leukotriene B4, a leukocyte 
activator, by activating  and  oxidation of fatty acids [23]. 
Furthermore, by suppressing the activation of the nuclear 
factor-kappaB (NF-kappaB), fibrates decrease the levels of 
interleukins 1 and 6 and cyclooxygenase 2 and subsequently 
the production of prostaglandin E2 and immunoglobulin 
[24]. The fibrate-associated increase in apolipoprotein A-II 
levels leads to suppressed expression of intercellular adhe-
sion molecule 1 and vascular cell adhesion molecule 1 [25]. 
Of note, these adhesion molecules are involved in the in-
flammatory process in the biliary system [26]. It is, there-
fore, likely that these PPAR-mediated anti-inflammatory 
and immunomodulatory effects of fenofibrate contribute to 
the improvement of PBC.  
  Biliary fibrosis in PBC results from cholestasis and intra-
hepatic accumulation of cytotoxic bile acids [1]. Fibrates 
facilitate the expression of the multiple drug resistance gene 
3 which encodes the canalicular phospholipid translocator 
[27, 28]. This receptor increases biliary phospholipid secre-
tion and induces the formation of micelles with hydrophobic 
bile acids, thus inactivating the latter and protecting biliary 
epithelial cells [27, 28]. 
  Furthermore, bile acids increase the expression of regu-
lated on activation normal T-cell expressed and secreted 
(RANTES), which migrates memory type CD4+ T-
lymphocytes to inflamed tissues, in the hepatocytes of pa-
tients with PBC [29]. Bezafibrate and fenofibrate decrease 
the chenodeoxycholic acid- and tumor necrosis factor--
induced mRNA expression and production of RANTES pro-
tein in human hepatoma cells [30, 31]. These findings indi-
cate that fibrates may inhibit inflammatory cell migration by 
RANTES to the liver in patients with PBC. 
  The ‘hepatic’ safety of fibrates has been confirmed by 
large clinical studies, while most of the adverse effects asso-
ciated with fibrate treatment have been scarce [32].  
  It has not been clarified whether the lipid abnormalities 
in PBC are associated with increased risk for CVD [12]. 
Overall, data do not support a strong association between 
excess CVD risk and PBC. In this context, it has been sug-
gested that hypercholesterolemia should be treated when 
other risk factors exist [33-35]. Statins, the mainstay of lipid 
lowering therapy, have been found to be safe and effective in 
improving the lipid profile in PBC patients,[36-40] overcom-
ing the concerns about inducing elevations of liver enzymes 
[41]. However, statins do not seem to ameliorate cholestasis 
or progression of the disease;[38] none of these studies   
included histological findings.  
  Of note, fenofibrate has been associated with some bene-
ficial effects on vascular events in patients with diabetes, 
[42] as well as with improvement (liver function tests and 
ultrasound) in non-alcoholic fatty liver disease [43]. How-
ever, as for statins, large, controlled, long-term studies are 
warranted to evaluate the efficacy of fibrates on histological 
improvement, symptom control and survival in patients with 
PBC. 
  Interestingly, the reduction in GT may be clinically 
relevant in terms of CVD risk. Indeed, evidence suggests 
that the serum GT concentration is an independent prognos-
tic factor for CVD, including coronary heart disease, diabe-
tes, stroke and CVD mortality [44-48]. Furthermore, GT 
levels have been positively correlated with several other car-
diovascular risk factors (e.g. LDL-C, triglycerides, uric acid, 
BMI, serum glucose, metabolic syndrome, smoking, hyper-
tension and prehypertension),[46, 47, 49] some of which are 
commonly found in patients with PBC. 
  The main limitations of this study are the small sample 
size and the lack of histological assessment after treatment. 
However, most of the studies that investigated the effects of 
fibrates in PBC were small and mainly only assessed bio-
chemical markers. Therefore, there is no definite evidence to 
support the histological improvement or the delay of disease 
progression after treatment with fibrates. On the other hand, 
the design of this study is relevant to clinical practice, i.e. 
what options are available when patients fail to achieve a 
biochemical response while on UDCA monotherapy. In ad-
dition, most studies did not record the lipid levels. The issue 
of CVD risk in patients with PBC warrants further investiga-
tion. 
  Our data, along with others, suggest that the addition   
of fenofibrate is safe and probably a useful option in this 
setting. 
CONCLUSION 
  UDCA is currently the most commonly used drug for   
the treatment of PBC. However, several patients do not 
achieve full biochemical response with UDCA and need 
supplementary treatment. Fibrates may improve the bio-
chemical and probably the histological abnormalities in 
PBC. Fenofibrate, a widely available and potent fibrate, 
seems to be a safe alternative or adjunct therapeutic option 
and simultaneously improve the lipid profile (and possibly 
vascular risk) in patients with incomplete response to 
UDCA.  
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